{
    "clinical_study": {
        "@rank": "73879", 
        "arm_group": {
            "arm_group_label": "TD-9855", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the absorption, distribution, metabolism, and\n      excretion (ADME) of a single oral dose of [14C]TD-9855"
        }, 
        "brief_title": "TD-9855 Mass Balance Study", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ADHD", 
            "Fibromyalgia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, nonsmoking male subjects or healthy, nonsmoking female subjects not of\n             childbearing potential, 18 to 50 years old, inclusive.  Women are considered to be\n             not of childbearing potential if they have had a hysterectomy or tubal ligation or\n             are at least 2 years postmenopausal (follicle-stimulating hormone [FSH] >40 IU/mL)\n\n          -  Body mass index 19 to 31 kg/m2, inclusive, and weight at least 55 kg\n\n          -  Negative for hepatitis B, hepatitis C, and HIV antibody\n\n        Exclusion Criteria:\n\n          -  Have evidence or history of clinically significant allergic (except for untreated,\n             asymptomatic, seasonal allergies at time of dosing), hematological, endocrine,\n             dermatologic, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or\n             neurological disease\n\n          -  Subjects who, in the opinion of the investigator, are at risk for suicide or risk of\n             harming others, or who score positive on the C-SSRS (item 2 or higher on ideation).\n             Subjects with any history of suicide attempts\n\n          -  Any condition possibly affecting drug absorption (e.g., previous surgery on the\n             gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall\n             bladder, or pancreas])\n\n          -  Infrequent bowel movements (less than once per 24 hours) in the last 7 days prior to\n             Day -1. Subject is unable to provide a fecal sample prior to study drug dosing on Day\n             -1 or Day 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924143", 
            "org_study_id": "0105"
        }, 
        "intervention": {
            "arm_group_label": "TD-9855", 
            "description": "radiolabeled (100 \u00b5Ci [14C]-Labeled) TD-9855 (20 mg)", 
            "intervention_name": "TD-9855", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ADHD", 
            "Fibromyalgia"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "TBD", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "TBD"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 \u00b5Ci [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Urinary and fecal recovery of total radioactivity. Whole blood and plasma concentrations of total radioactivity.", 
            "measure": "To define the routes and rates of elimination and mass balance of [14C]-labeled TD-9855", 
            "safety_issue": "No", 
            "time_frame": "1-21 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Whole blood and plasma concentrations", 
                "measure": "Pharmacokinetics of total drug-related material and TD-9855: Cmax", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "description": "Whole blood and plasma concentrations", 
                "measure": "PK: Tmax", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "description": "Whole blood and plasma concentrations", 
                "measure": "PK: AUCt", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "measure": "PK: AUCinf", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "description": "Urine", 
                "measure": "PK: CL/F (Renal clearance)", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "measure": "PK: Vz/F (oral volume of distribution during the terminal phase)", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "description": "Urine", 
                "measure": "PK: amount excreted in urine (Ae)", 
                "safety_issue": "No", 
                "time_frame": "1-21 Days"
            }, 
            {
                "description": "Urine", 
                "measure": "PK: CLR (Renal clearance, computed as amount recovered in urine/ AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "8-21 Days"
            }, 
            {
                "measure": "Metabolic profiles in plasma and excreta", 
                "safety_issue": "No", 
                "time_frame": "1-21 days"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}